TrialFinder  /  Landscape Report OCD  ·  2026-07-17 Revasser  /  revasserkernel.com
Landscape Report TrialFinder
SOURCE  ClinicalTrials.gov API v2
GENERATED  2026-07-17
VERSION  v1
SAMPLE  100 of 6574 studies

ocd

The ocd clinical trial landscape includes 6574 actively recruiting trials. Semantic expansion identified 6448 additional trials beyond exact-match search, representing a 5117.5% discovery lift across related conditions and therapeutic approaches.

Recruiting
6574
active trials
Expansion Lift
+5117.5%
6448 additional trials
Top Sponsor
The University of Texas Health Science Center at San Antonio
2 trials
Dominant Phase
NA
61 of 105 sampled
Pipeline Overview
Phase Distribution
NA
61
Early I
2
Phase 1
3
Phase 2
10
Phase 3
6
Phase 4
1
Other
22
Therapeutic Modalities
BEHAVIORAL
60
DRUG
34
OTHER
32
DEVICE
26
DIAGNOSTIC_TEST
11
DIETARY_SUPPLEMENT
2
GENETIC
1
COMBINATION_PRODUCT
1
Recruiting vs. Completed (2yr)
Recruiting
6574
Completed
4299
Competitive Landscape
Sponsor Classification
91%
4%
4%
OTHER (21)
INDUSTRY (1)
FED (1)
Top Sponsors
SponsorTrialsClass
The University of Texas Health Science Center at San Antonio2OTHER
University of California, Los Angeles2OTHER
University of California, San Francisco2OTHER
University of Pittsburgh2OTHER
Medical University of South Carolina2OTHER
Washington University School of Medicine2OTHER
Stanford University2OTHER
University of Alabama at Birmingham2OTHER
Idorsia Pharmaceuticals Ltd.1INDUSTRY
Texas A&M University1OTHER
Al-Hawash Private University1OTHER
Universidad de Santander1OTHER
Göteborg University1OTHER
Walter Reed Army Institute of Research (WRAIR)1FED
Unity Health Toronto1OTHER
Geographic Distribution
Top U.S. States by Trial Density
StateTrialsTop City
California30Los Angeles
Florida23Miami
Texas13San Antonio
Georgia11Atlanta
New York11New York
Pennsylvania8Pittsburgh
Maryland7Baltimore
Massachusetts7Boston
Ohio7Cincinnati
South Carolina5Charleston
Alabama5Birmingham
Illinois5Chicago
Missouri5St Louis
Michigan5Lansing
North Carolina4Durham
Utah4Salt Lake City
Arizona4Phoenix
Connecticut4New Haven
Washington4Bellevue
Virginia3Fairfax
Expansion Intelligence
+5117.5%
Discovery lift — trials found by semantic expansion that exact-match search misses entirely. This is the gap competitors don't see.
2
Exact
2
Parent
4
Related
4
Comorbid
5
Therapeutic
Top Expansion Terms
  • anxiety disorder Parent
  • psychiatric disorder Parent
  • body dysmorphic disorder Related
  • hoarding disorder Related
  • trichotillomania Related
  • excoriation disorder Related
  • depression Comorbid
  • anxiety Comorbid
  • tic disorder Comorbid
  • eating disorder Comorbid

These terms are curated from clinical literature — not generated by a language model. Each captures trials that use variant nomenclature for the same underlying condition or therapeutic area.

Key Findings
What This Landscape Means for ocd
high
Standard searches miss 5118% of relevant trials for ocd — semantic expansion across related conditions and therapeutic approaches is essential for complete landscape visibility.
6448 additional trials found via expansion vs 126 exact matches
high
6 Phase 3 trials indicate a maturing pipeline with near-term approval potential.
Phase 3 represents 6% of sampled trials
Next Steps
Take Action on This Intelligence
//
Stay Current
Get alerted when new trials open for ocd and related conditions. Free tier monitors 1 condition weekly.
Set Up Alerts
[+]
Research Portal
Deploy this intelligence as your organization's permanent research hub — auto-updating, branded, zero hosting cost.
From $497
{<}
API Access
Integrate trial intelligence into your own tools. Full expansion engine, landscape analytics, real-time data.
View Plans
Top Recruiting Trials
20 actively recruiting studies
Registry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQ®
Idorsia Pharmaceuticals Ltd. n=785 IQVIA US Office Durham, North Carolina
Intervention DRUG: Daridorexant — Dosing and treatment duration of QUVIVIQ as part of this observational study is at the discretion of the healthcare prov...
Eligibility Ages 15 Years – 50 Years, FEMALE only
Contact Clinical Trial Information USA · +1 856 661 37 21 · idorsiaclinicaltrials@idorsia.com
NCT05959434 PHASE2
Integration of Cognitive Processing Therapy and Relapse Prevention for Alcohol Use Disorder and PTSD
Texas A&M University n=200 Medical University of South Carolina Charleston, South Carolina
Intervention BEHAVIORAL: Cognitive Processing Therapy + Relapse Prevention — Cognitive-Behavioral Therapy that integrates Cognitive Processing Therapy for PTSD with Relapse Prevention for alcohol u...
Eligibility Ages 18 Years
Contact Anka A Vujanovic, Ph.D. · 979-862-6538 · avujanovic@tamu.edu
Bruxism, Anxiety, and Periodontal Status Among Dental Students
Al-Hawash Private University n=100 Al-Hawash Private University, Faculty of Dentistry Homs
Eligibility Ages 18 Years
Contact Ali Abou Sulaiman, Ph.D. in Periodontology · +963956790836 · dr.ali.abousulaiman@hpu.edu.sy
Efficacy of a Multicomponent Intervention on Cognitive Function for the Caregiver-patient Dyad
Universidad de Santander n=102 Universidad de Santander / Universidad Manuela Beltrán /FOSCAL Bucaramanga, Santander Department
Intervention OTHER: Multi-component, transdisciplinary and multifocal intervention for the cognition — Multi-component intervention (12 weeks, twice/week, with professional support at home) Physical activity for the patien...
Eligibility Ages 55 Years
Contact Diana Tiga Loza, Ph.D · +57 (607) 6516500 · dia.tiga@mail.udes.edu.co
iCBT for Seniors With Depression in Primary Care
Göteborg University n=390 University of Gothenburg Gothenburg
Intervention BEHAVIORAL: iCBT for depression — iCBT depression program with minimal therapist contact offered within 14 days from inclusion and with a duration of 10-1...
Eligibility Ages 65 Years
Contact Dominique Hange, Ass Prof · +46722 245 700 · dominique.hange@allmed.gu.se
NCT06982183 PHASE4
The Effects of Propranolol and Hydrocortisone on Military-Relevant Performance Outcomes
Walter Reed Army Institute of Research (WRAIR) n=88 Sleep Research Center (SRC), Walter Reed Army Institute of Research Silver Spring, Maryland
Intervention DRUG: Propranolol — An administration of a 40-mg propranolol capsule immediately after tarantula exposure
Eligibility Ages 18 Years – 40 Years
Contact John Hughes, MD · 301-319-3214 · john.d.hughes4.civ@health.mil
Characterizing Dopamine Receptor Binding in Treatment Resistant Depression
Unity Health Toronto n=45 Unity Health Toronto Toronto, Ontario
Intervention DIAGNOSTIC_TEST: PET scans — PET scans and PHNO scans
Eligibility Ages 25 Years – 55 Years
Contact Sakina J Rizvi, PhD · 416-864-6060 · rizvis@smh.ca
Longitudinal Cognitive Assessment by BoCA
Alzheimer's Light LLC n=10000 Andrey Vyshedskiy Miami, Florida
Intervention DIAGNOSTIC_TEST: Boston Cognitive Assessment (BoCA) — The Boston Cognitive Assessment (BoCA) is a self-administered online test intended for longitudinal cognitive monitoring...
Eligibility Ages 50 Years
Contact ANDREY VYSHEDSKIY, Ph.D. · 6174338577 · vysha@bu.edu
Targeting Repetitive Behaviors in Autism Spectrum Disorder Via Transcranial Direct Current Stimulation
Bambino Gesù Hospital and Research Institute n=78 Bambino Gesù Children Hospital Rome, Italy
Intervention DEVICE: Active HD-tDCS over pre-SMA — Active cathodal HD-tDCS over pre-SMA cortex will be delivered for 10 days (3 sessions per week). The 4 × 1 montage using...
Eligibility Ages 8 Years – 13 Years
Virtual Reality for Recovery After Intensive Care (PICS)
University of Minho n=51 Centro Hospitalar Universitário São João Porto, Porto District
Intervention DEVICE: Immersive VR Multi-Domain Rehabilitation — A bedside multi-domain rehabilitation program using a head-mounted display. Participants perform 6 gamified tasks target...
Eligibility Ages 18 Years
Contact Nuno F. Rodrigues · 929145931 · nunofeixa@gmail.com
Retinal Vessel Leakage in Cerebral Small Vessel Disease
University of Edinburgh n=40 NHS Lothian Edinburgh
Intervention DIAGNOSTIC_TEST: Fundus fluorescein angiography, with ultrawide field retinal imaging — Intravenous injection of sodium fluorescein for angiography of retinal blood vessels
Eligibility Ages 18 Years
NCT06902298 PHASE1, PHASE2
Personalized Ultrasonic Brain Stimulation for Depression (R61)
Brian Mickey n=30 University of Utah Salt Lake City, Utah
Intervention DEVICE: LTFUS to SCC — Low-intensity transcranial focused ultrasound delivered to subgenual cingulate cortex
Eligibility Ages 18 Years – 65 Years
Contact Brian J Mickey · 801-587-0159 · brian.mickey@utah.deu
COpenhagen Magnetic Personalized Accelerated Brain Circuit Therapy for Treatment Resistant Depression
Danish Research Centre for Magnetic Resonance n=78 Centre of Neuropsychiatric Depression Research Glostrup Municipality
Intervention DEVICE: MagVenture XP Orange Stimulator and active side of MagVenture COOL-B65 coil. — Intermittent theta burst stimulation (iTBS) targeting the left dorsolateral prefrontal cortex (DLPFC) will be administer...
Eligibility Ages 18 Years – 95 Years
Contact Poul Videbech, Professor · +4538640634 · poul.videbech@regionh.dk
Shared Decision Making in PTSD Treatment
The University of Texas Health Science Center at San Antonio n=200 Carl R. Darnall Army Medical Center (CRDAMC) Fort Cavazos, Texas
Intervention BEHAVIORAL: Prolonged Exposure Therapy — PE is a cognitive-behavioral treatment for PTSD that is typically delivered in ten 90-minute sessions . For the current ...
Eligibility Ages 18 Years
Contact Vanessa Jacoby, PhD · 254-289-3468 · jacobyv@uthscsa.edu
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
Sunnybrook Health Sciences Centre n=88 Sunnybrook Health Sciences Centre Toronto, Ontario
Intervention DEVICE: rTMS — Accelerated iTBS treatment
Eligibility Ages 20 Years – 65 Years
Contact Anusha Baskaran, PhD · 416-480-6100 · anusha.baskaran@sunnybrook.ca
NCT06633016 PHASE2
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
Autobahn Therapeutics, Inc. n=230 Autobahn Site #131 Birmingham, Alabama
Intervention DRUG: ABX-002 — ABX-002 oral solution in 1-mL cyclic olefin polymer prefilled syringes, taken on an empty stomach first thing in the mor...
Eligibility Ages 18 Years – 65 Years
Contact Ashlee Heldreth, MS · 8582573418 · clinicaltrials@autobahntx.com
NCT05754073 PHASE2
Oxytocin Effects on Bone in Children With Autism Spectrum Disorder
Elizabeth Austen Lawson n=96 Massachusetts General Hospital Boston, Massachusetts
Intervention DRUG: 1. Intranasal oxytocin spray — 30 IU, twice daily for 12 months in the experimental arm in double-blinded phase
Eligibility Ages 6 Years – 18 Years
Contact Madhusmita Misra, MD, MPH · 434-924-9141 · abp6bd@uvahealth.org
Functional Near-infrared Spectroscopy for Anxiety Monitoring and Neurofeedback.
National Taiwan University Hospital n=232 National Taiwan University Hospital Taipei
Intervention DEVICE: AI-fNIRS neurofeedback device — The device, with AI-fNIRS signals serving as brain monitor to indicate the level of anxiety, provides mindfulness traini...
Eligibility Ages 18 Years
Contact Yi-Jing Huang, Assistant Professor · +886911164386 · yijinghuang@ntu.edu.tw
Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans
University Hospital, Gentofte, Copenhagen n=18 Center for Clinical Metabolic Research, Gentofte Hospital Hellerup, Capital Region
Intervention DRUG: Amylin (Pramlintide) — This a one of the pancreatic hormones investigated in this study. Pramlintide is used a surrogate for amylin due to the ...
Eligibility Ages 18 Years – 65 Years, MALE only
Contact Andreas H Lange · +4553807019 · andreas.holst.lange@rehionh.dk
NCT06767683 PHASE2, PHASE3
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
Alkermes, Inc. n=256 Alkermes Investigator Site Phoenix, Arizona
Intervention DRUG: ALKS 2680, 4mg — Oral tablet containing 4 mg of ALKS 2680 for once daily administration
Eligibility Ages 18 Years – 70 Years
Contact Director, Global Clinical Services · 888-235-8008 (US Only) · clinicaltrials@alkermes.com